Sponsor Pipeline

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
2
Recruiting
2
Phase 3
3
Disease Areas
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-11 NCT07654374
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus…		 Recruitment opened
2026-08-11 NCT07654361
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a…		 Recruitment opened
2026-08-11 NCT06693843
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of…		 Trial completed
Active Trials by Phase
Phase 3
2
Phase 2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07654361 Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a… Obesity Recruiting
NCT07654374 A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus… Obesity Recruiting
Phase 2
NCT07169942 Aleniglipron Phase 2 Body Composition Study Obesity, Overweight, or Chronic Weight Management Active, Not Recruiting
NCT07400588 Aleniglipron Phase 2 in Type 2 Diabetes Mellitus Obese Active, Not Recruiting
Disease Areas
Obesity (4) Diabetes (2) Type 2 Diabetes (1)
Get alerts when Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free